Galkanezumab, eptinezumab and fremanezumab
New migraine medications have demonstrated effectiveness
Anna Stavina, XX2 century, based on Medscape: Galcanezumab Reduces Migraine Days in Phase 3 Trials
Adult patients suffering from episodic or chronic migraine attacks can alleviate their disease with the help of a new drug, according to the results of a recently completed study. We are talking about an antibody to a peptide encoded by the calcitonin gene (or calcitonin-bound peptide). The international nonproprietary name of the drug is galcanezumab (galcanezumab). The drug was developed by a pharmaceutical company Eli Lilly and Company.
To date, phase III clinical trials have been successfully completed. The results of the work are presented in the reports and poster sessions of the Annual Scientific Meeting of the American Headache Society.
The drug was studied in two clinical trials, EVOLVE-1 and EVOLVE-2 with an almost identical design. In total, more than 1,700 volunteers with episodic migraine attacks took part in the trials. Study participants who took 120 or 240 mg of galcanezumab demonstrated a significant reduction in the number of days with seizures compared to those who received a placebo.
The secondary endpoint of the trials, the authors of the studies chose to reduce the number of days with migraine attacks by 50, 70 or 100%. In the experimental groups, it was also achieved significantly more often than in the control groups.
In the work of REGAIN, which involved patients with chronic migraine, similar results were achieved.
"We are very pleased with the results obtained. The data from all three studies are in good agreement with each other, as well as with the results of other studies of the class of drugs," says Dr. Eric Pearlman, medical director of the headache department of the American representative office Eli Lilly. Dr. Perlman also reported that in The data will be presented by the Food and Drug Administration in the second half of 2017.
Also, during the meeting of the American Headache Society, positive results of phase III clinical trials of HALO-CM and HALO-EM were presented. In the course of these studies, another drug of the same pharmacological group was studied, fremanezumab, developed by Teva Pharmaceuticals Industries Ltd., a means to combat chronic and episodic migraine attacks.
Another drug, eptinezumab (eptinezumab) with the same indications has successfully passed phase II clinical trials.
"This is the first class of drugs developed specifically for the treatment of migraines. All other means used to combat migraines were originally created for the treatment of other diseases," explains Dr. Perlman. – I think that is why the listed drugs aroused great interest among the participants of the meeting. But at the same time, this indicates an unmet need for migraine treatment in patients with this diagnosis."
Portal "Eternal youth" http://vechnayamolodost.ru
20.06.2017